Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002603.SZ

Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2023: USD 322.08 M

Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA is USD 322.08 M for the year ending December 31, 2023, a -32.30% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 475.76 M, a 54.45% change year over year.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 308.03 M, a 17.60% change year over year.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 261.93 M, a 86.48% change year over year.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 140.46 M, a 0.54% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
Shenzhen Stock Exchange: 002603.SZ

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

CEO Mr. Xiang Jun Wu
IPO Date July 28, 2011
Location China
Headquarters No. 238 Tianshan Street
Employees 13,958
Sector Health Care
Industries
Description

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.

StockViz Staff

January 15, 2025

Any question? Send us an email